1-17 of 17
Brian A. Van Tine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bcl-Xl Protects ASS1-Deficient Cancers From Arginine Starvation Induced Apoptosis

Prashanta Kumar. Panda, Ana Carolina. Paschoalini Mafra, Alliny C. S. Bastos, Li Cao, Maria Serra Bonet, Caitlyn B. Brashears, Ethan Yang. Chen, Heather M. Benedict-Hamilton, William Ehrhardt, John Bomalaski, Carina Dehner, Leonard C. Rogers, Toshinao Oyama, Brian A. Van Tine
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-2548
Published: 03 February 2025
View article titled, Bcl-Xl Protects ASS1-Deficient Cancers From Arginine Starvation Induced Apoptosis
Open the PDF for Bcl-Xl Protects ASS1-Deficient Cancers From Arginine Starvation Induced Apoptosis in another window
Includes: Supplementary data
Journal Articles

Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?

Brian A. Van Tine, Sasha Haarberg
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4552–4553.
https://doi.org/10.1158/1078-0432.CCR-24-1628
Published: 15 October 2024
View article titled, Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?
Open the PDF for Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials? in another window
Journal Articles

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Mia C. Weiss, Vanessa Eulo, Brian A. Van Tine
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 649–651.
https://doi.org/10.1158/1078-0432.CCR-23-2787
Published: 16 February 2024
View article titled, To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma
Open the PDF for To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma in another window
Journal Articles

Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Leonard C. Rogers, Jeff C. Kremer, Caitlyn B. Brashears, Zongtao Lin, Zhixian Hu, Alliny C.S. Bastos, Adriana Baker, Nicole Fettig, Dong Zhou, Kooresh I. Shoghi, Carina A. Dehner, John S.A. Chrisinger, John S. Bomalaski, Benjamin A. Garcia, Toshinao Oyama, Eileen P. White, Brian A. Van Tine
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3189–3202.
https://doi.org/10.1158/1078-0432.CCR-22-2642
Published: 15 August 2023
View article titled, Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
Open the PDF for Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment in another window
Includes: Supplementary data
Journal Articles

A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma

Matthew Ingham, Shing Lee, Brian A. Van Tine, Edwin Choy, Jay Oza, Sahil Doshi, Liner Ge, Peter Oppelt, Gregory Cote, Brian Corgiat, Naomi Sender, Sarah Sta Ana, Lavan Panchalingam, Emmanuel Petricoin, Gary K. Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1031–1039.
https://doi.org/10.1158/1078-0432.CCR-22-3351
Published: 14 March 2023
View article titled, A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma
Open the PDF for A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma in another window
Includes: Supplementary data
Journal Articles

Abstract A038: Enrollment of pediatric and adolescent patients with MAGE-A4+ advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4])

Colin Lunt, Sandra P. D’Angelo, Albiruni Ryan Abdul Razak, Michael J. Wagner, Brian A. Van Tine, Kristen Ganjoo, Jean-Yves Blay, Dejka M. Araujo, Mark Agulnik, John W. Glod, Erin Van Winkle, Erica Elefant, Swethajit Biswas, Dennis Williams, Axel Le Cesne
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A038.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A038
Published: 15 September 2022
View article titled, Abstract A038: Enrollment of pediatric and adolescent patients with MAGE-A4+ advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4])
Journal Articles

Abstract IA022: Arginine, serine, xCT and ME, the therapeutic metabolism of different sarcomas

Brian A. Van Tine
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): IA022.
https://doi.org/10.1158/1557-3265.SARCOMAS22-IA022
Published: 15 September 2022
View article titled, Abstract IA022: Arginine, serine, xCT and ME, the therapeutic metabolism of different sarcomas
Journal Articles

Are the Pieces Starting to Come Together for Management of Desmoid Tumors?

Anna C. Greene, Brian A. Van Tine
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 3911–3913.
https://doi.org/10.1158/1078-0432.CCR-22-0620
Published: 15 September 2022
View article titled, Are the Pieces Starting to Come Together for Management of Desmoid Tumors?
Open the PDF for Are the Pieces Starting to Come Together for Management of Desmoid Tumors? in another window
Journal Articles

Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102

Caitlyn B. Brashears, Bethany C. Prudner, Richa Rathore, Katharine E. Caldwell, Carina A. Dehner, Jane L. Buchanan, Sara E.S. Lange, Neal Poulin, Jennifer K. Sehn, Jason Roszik, Dirk Spitzer, Kevin B. Jones, Regis O'Keefe, Torsten O. Nielsen, Eric B. Taylor, Jason M. Held, William Hawkins, Brian A. Van Tine
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3573–3589.
https://doi.org/10.1158/1078-0432.CCR-22-0470
Published: 15 August 2022
View article titled, Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
Open the PDF for Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102 in another window
Includes: Supplementary data
Journal Articles

In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Brian A. Van Tine, Costas A. Lyssiotis
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1477–1478.
https://doi.org/10.1158/1078-0432.CCR-21-4180
Published: 14 April 2022
View article titled, In an Era of ctDNA, Is Metabolomics the New Kid on the Block?
Open the PDF for In an Era of ctDNA, Is Metabolomics the New Kid on the Block? in another window
Journal Articles

Truly Man's Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma

Mia C. Weiss, Vanessa Eulo, Brian A. Van Tine
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 571–572.
https://doi.org/10.1158/1078-0432.CCR-21-3471
Published: 15 February 2022
View article titled, Truly Man's Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma
Open the PDF for Truly Man's Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma in another window
Journal Articles

A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Gulam A. Manji, Brian A. Van Tine, Shing M. Lee, Alexander G. Raufi, Ilenia Pellicciotta, Angela C. Hirbe, Jaya Pradhan, Andrew Chen, Raul Rabadan, Gary K. Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5519–5527.
https://doi.org/10.1158/1078-0432.CCR-21-1779
Published: 15 October 2021
View article titled, A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Open the PDF for A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors in another window
Includes: Supplementary data
Journal Articles

Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

Robin L. Jones, Andrew J. Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A. Van Tine, Javier Martín-Broto, Patrick M. Peterson, Jennifer Wright, William D. Tap
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3861–3866.
https://doi.org/10.1158/1078-0432.CCR-20-4592
Published: 15 July 2021
View article titled, Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial
Open the PDF for Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma

Brian A. Van Tine, Angela C. Hirbe, Peter Oppelt, Ashley E. Frith, Richa Rathore, Joshua D. Mitchell, Fei Wan, Shellie Berry, Michele Landeau, George A. Heberton, John Gorcsan, III, Peter R. Huntjens, Yoku Soyama, Justin M. Vader, Jose A. Alvarez-Cardona, Kathleen W. Zhang, Daniel J. Lenihan, Ronald J. Krone
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3854–3860.
https://doi.org/10.1158/1078-0432.CCR-20-4621
Published: 15 July 2021
View article titled, Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma
Open the PDF for Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma in another window
Journal Articles

Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas

Javier Martín-Broto, David S. Moura, Brian A. Van Tine
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5801–5808.
https://doi.org/10.1158/1078-0432.CCR-19-3335
Published: 13 November 2020
View article titled, Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas
Open the PDF for Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas in another window
Journal Articles

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

Emily Z. Keung, Melissa Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, Steven Attia, Richard F. Riedel, James Hu, Scott H. Okuno, Dennis A. Priebat, Sujana Movva, Lara E. Davis, Damon R. Reed, Alexandre Reuben, Christina L. Roland, Denise Reinke, Alexander J. Lazar, Wei-Lien Wang, Jennifer A. Wargo, Hussein A. Tawbi
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1258–1266.
https://doi.org/10.1158/1078-0432.CCR-19-1824
Published: 13 March 2020
View article titled, Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Open the PDF for Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Arginine Starvation and Docetaxel Induce c-Myc–Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors

Bethany C. Prudner, Richa Rathore, Anthony M. Robinson, Abigail Godec, Samuel F. Chang, William G. Hawkins, Angela C. Hirbe, Brian A. Van Tine
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (16): 5122–5134.
https://doi.org/10.1158/1078-0432.CCR-19-0206
Published: 15 August 2019
View article titled, Arginine Starvation and Docetaxel Induce c-Myc–Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors
Open the PDF for Arginine Starvation and Docetaxel Induce c-Myc–Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors in another window
Includes: Supplementary data